SGLT2 Inhibitors SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin) being approved in 2013 and the newest one (Ertugliflozin) being approved this year. These work by inhibiting glucose reabsorption in the nephron (kidney), which causes the patient to excrete glucose in the urine. Benefits of these drugs include side effects of weight loss (potentially water weight) and blood pressure lowering. Some people call these drugs "glucoretics", since they are similar to diuretics but for glucose. Side effects include UTI's due to increased glucose excretion in the urine, and patients need to have good kidney function for these drugs to be used. Each is available as a combo product with metformin, and a few others as well! Jarred Prudencio, PharmD - https://www.instagram.com/ambcarerx #SGLT2 #Inhibitors #Pharmacology #Medications #DM2 #Diabetes #Endocrinology
